|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LATS1 |
Gene summary for LATS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LATS1 | Gene ID | 9113 |
| Gene name | large tumor suppressor kinase 1 | |
| Gene Alias | WARTS | |
| Cytomap | 6q25.1 | |
| Gene Type | protein-coding | GO ID | GO:0000079 | UniProtAcc | O95835 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9113 | LATS1 | LZE4T | Human | Esophagus | ESCC | 2.28e-14 | 4.14e-01 | 0.0811 |
| 9113 | LATS1 | LZE7T | Human | Esophagus | ESCC | 4.06e-11 | 5.08e-01 | 0.0667 |
| 9113 | LATS1 | LZE8T | Human | Esophagus | ESCC | 3.83e-03 | 2.12e-01 | 0.067 |
| 9113 | LATS1 | LZE24T | Human | Esophagus | ESCC | 6.42e-14 | 3.31e-01 | 0.0596 |
| 9113 | LATS1 | LZE6T | Human | Esophagus | ESCC | 3.34e-04 | 1.51e-01 | 0.0845 |
| 9113 | LATS1 | P1T-E | Human | Esophagus | ESCC | 4.35e-12 | 3.14e-01 | 0.0875 |
| 9113 | LATS1 | P2T-E | Human | Esophagus | ESCC | 2.91e-20 | 3.61e-01 | 0.1177 |
| 9113 | LATS1 | P4T-E | Human | Esophagus | ESCC | 3.05e-17 | 2.85e-01 | 0.1323 |
| 9113 | LATS1 | P5T-E | Human | Esophagus | ESCC | 5.50e-10 | 1.44e-01 | 0.1327 |
| 9113 | LATS1 | P8T-E | Human | Esophagus | ESCC | 1.02e-19 | 1.99e-01 | 0.0889 |
| 9113 | LATS1 | P9T-E | Human | Esophagus | ESCC | 3.49e-12 | 1.37e-01 | 0.1131 |
| 9113 | LATS1 | P10T-E | Human | Esophagus | ESCC | 3.42e-18 | 2.43e-01 | 0.116 |
| 9113 | LATS1 | P11T-E | Human | Esophagus | ESCC | 1.56e-13 | 3.81e-01 | 0.1426 |
| 9113 | LATS1 | P12T-E | Human | Esophagus | ESCC | 4.29e-11 | 2.70e-01 | 0.1122 |
| 9113 | LATS1 | P15T-E | Human | Esophagus | ESCC | 1.46e-12 | 3.73e-01 | 0.1149 |
| 9113 | LATS1 | P16T-E | Human | Esophagus | ESCC | 1.98e-30 | 5.35e-01 | 0.1153 |
| 9113 | LATS1 | P17T-E | Human | Esophagus | ESCC | 5.19e-07 | 1.69e-01 | 0.1278 |
| 9113 | LATS1 | P20T-E | Human | Esophagus | ESCC | 1.43e-12 | 2.68e-01 | 0.1124 |
| 9113 | LATS1 | P21T-E | Human | Esophagus | ESCC | 1.08e-20 | 3.16e-01 | 0.1617 |
| 9113 | LATS1 | P22T-E | Human | Esophagus | ESCC | 1.55e-14 | 1.53e-01 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00459367 | Liver | NAFLD | negative regulation of phosphate metabolic process | 73/1882 | 441/18723 | 1.31e-05 | 3.93e-04 | 73 |
| GO:00105637 | Liver | NAFLD | negative regulation of phosphorus metabolic process | 73/1882 | 442/18723 | 1.42e-05 | 4.17e-04 | 73 |
| GO:00513487 | Liver | NAFLD | negative regulation of transferase activity | 49/1882 | 268/18723 | 2.61e-05 | 7.03e-04 | 49 |
| GO:00301115 | Liver | NAFLD | regulation of Wnt signaling pathway | 57/1882 | 328/18723 | 2.79e-05 | 7.46e-04 | 57 |
| GO:00329707 | Liver | NAFLD | regulation of actin filament-based process | 66/1882 | 397/18723 | 2.92e-05 | 7.72e-04 | 66 |
| GO:00329567 | Liver | NAFLD | regulation of actin cytoskeleton organization | 60/1882 | 358/18723 | 5.20e-05 | 1.20e-03 | 60 |
| GO:01100537 | Liver | NAFLD | regulation of actin filament organization | 49/1882 | 278/18723 | 6.88e-05 | 1.46e-03 | 49 |
| GO:0044772 | Liver | NAFLD | mitotic cell cycle phase transition | 67/1882 | 424/18723 | 1.25e-04 | 2.39e-03 | 67 |
| GO:0044843 | Liver | NAFLD | cell cycle G1/S phase transition | 43/1882 | 241/18723 | 1.40e-04 | 2.63e-03 | 43 |
| GO:00071793 | Liver | NAFLD | transforming growth factor beta receptor signaling pathway | 37/1882 | 198/18723 | 1.53e-04 | 2.82e-03 | 37 |
| GO:00434016 | Liver | NAFLD | steroid hormone mediated signaling pathway | 28/1882 | 136/18723 | 1.78e-04 | 3.14e-03 | 28 |
| GO:0000082 | Liver | NAFLD | G1/S transition of mitotic cell cycle | 39/1882 | 214/18723 | 1.78e-04 | 3.14e-03 | 39 |
| GO:00608285 | Liver | NAFLD | regulation of canonical Wnt signaling pathway | 44/1882 | 253/18723 | 2.14e-04 | 3.68e-03 | 44 |
| GO:00487327 | Liver | NAFLD | gland development | 67/1882 | 436/18723 | 2.83e-04 | 4.53e-03 | 67 |
| GO:00432547 | Liver | NAFLD | regulation of protein-containing complex assembly | 66/1882 | 428/18723 | 2.83e-04 | 4.53e-03 | 66 |
| GO:00600705 | Liver | NAFLD | canonical Wnt signaling pathway | 50/1882 | 303/18723 | 3.08e-04 | 4.83e-03 | 50 |
| GO:00512587 | Liver | NAFLD | protein polymerization | 49/1882 | 297/18723 | 3.54e-04 | 5.36e-03 | 49 |
| GO:00071784 | Liver | NAFLD | transmembrane receptor protein serine/threonine kinase signaling pathway | 56/1882 | 355/18723 | 4.50e-04 | 6.62e-03 | 56 |
| GO:00305185 | Liver | NAFLD | intracellular steroid hormone receptor signaling pathway | 24/1882 | 116/18723 | 4.64e-04 | 6.74e-03 | 24 |
| GO:00336736 | Liver | NAFLD | negative regulation of kinase activity | 40/1882 | 237/18723 | 7.49e-04 | 9.50e-03 | 40 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0439018 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| hsa0439019 | Esophagus | ESCC | Hippo signaling pathway | 92/4205 | 157/8465 | 1.46e-02 | 3.31e-02 | 1.69e-02 | 92 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LATS1 | SNV | Missense_Mutation | c.2259G>C | p.Glu753Asp | p.E753D | O95835 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| LATS1 | SNV | Missense_Mutation | c.3082C>G | p.Pro1028Ala | p.P1028A | O95835 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | |
| LATS1 | SNV | Missense_Mutation | c.2512C>G | p.Arg838Gly | p.R838G | O95835 | protein_coding | tolerated(0.28) | benign(0.408) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| LATS1 | SNV | Missense_Mutation | novel | c.2995A>G | p.Asn999Asp | p.N999D | O95835 | protein_coding | tolerated(0.14) | benign(0.05) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LATS1 | SNV | Missense_Mutation | novel | c.2869G>C | p.Glu957Gln | p.E957Q | O95835 | protein_coding | deleterious(0.04) | benign(0.411) | TCGA-BH-A0H5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| LATS1 | SNV | Missense_Mutation | c.108A>T | p.Glu36Asp | p.E36D | O95835 | protein_coding | deleterious_low_confidence(0.01) | benign(0.055) | TCGA-C8-A26V-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | CR | |
| LATS1 | SNV | Missense_Mutation | rs139248642 | c.3373C>T | p.Arg1125Cys | p.R1125C | O95835 | protein_coding | tolerated_low_confidence(0.17) | benign(0) | TCGA-OK-A5Q2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| LATS1 | insertion | In_Frame_Ins | novel | c.944_945insTAAATT | p.Gln315delinsHisLysLeu | p.Q315delinsHKL | O95835 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| LATS1 | insertion | In_Frame_Ins | novel | c.942_943insTATTTAACATTG | p.Asn314_Gln315insTyrLeuThrLeu | p.N314_Q315insYLTL | O95835 | protein_coding | TCGA-A8-A06P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | SD | |||
| LATS1 | SNV | Missense_Mutation | c.1604G>A | p.Gly535Glu | p.G535E | O95835 | protein_coding | tolerated(0.32) | benign(0) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |